Multi-Mission Power Analysis Tool (MMPAT) Version 3

The Multi-Mission Power Analysis Tool (MMPAT) simulates a spacecraft power subsystem including the power source (solar array and/or radioisotope thermoelectric generator), bus-voltage control, secondary battery (lithium-ion or nickel-hydrogen), thermostatic heaters, and power-consuming equipment. It handles multiple mission types including heliocentric orbiters, planetary orbiters, and surface operations. Being parametrically driven along with its user-programmable features can reduce or even eliminate any need for software modifications when configuring it for a particular spacecraft. It provides multiple levels of fidelity, thereby fulfilling the vast majority of a project s power simulation needs throughout the lifecycle. It can operate in a stand-alone mode with a graphical user interface, in batch mode, or as a library linked with other tools. This software can simulate all major aspects of a spacecraft power subsystem. It is parametrically driven to reduce or eliminate the need for a programmer. Added flexibility is provided through user-designed state models and table-driven parameters. MMPAT is designed to be used by a variety of users, such as power subsystem engineers for sizing power subsystem components; mission planners for adjusting mission scenarios using power profiles generated by the model; system engineers for performing system- level trade studies using the results of the model during the early design phases of a spacecraft; and operations personnel for high-fidelity modeling of the essential power aspect of the planning picture

PKC Activation in Niemann Pick C1 Cells Restores Subcellular Cholesterol Transport

Activation of protein kinase C (PKC) has previously been shown to ameliorate the cholesterol transport defect in Niemann Pick Type C1 (NPC1) cells, presumably by increasing the soluble levels of one of its substrates, vimentin. This activity would then restore the vimentin cycle in these cells and allow vimentin-dependent retrograde transport to proceed. Here, we further investigate the effects of PKC activation in NPC1 cells by evaluating different isoforms for their ability to solubilize vimentin and correct the NPC1 cholesterol storage phenotype. We also examine the effects of PKC activators, including free fatty acids and the PKC-specific activator diazoxide, on the NPC1 disease phenotype. Our results indicate that PKC isoforms α, βII, and ε have the greatest effects on vimentin solubilization. Furthermore, expression or activation of PKCε in NPC1 cells dramatically reduces the amount of stored cholesterol and restores cholesterol transport out of endocytic vesicles. These results provide further support for the contribution of PKCs in NPC1 disease pathogenesis and suggest that PKCs may be targeted in future efforts to develop therapeutics for NPC1 disease

Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis

Cyclodextrins (CDs) have long been used to manipulate cellular cholesterol levels both in vitro and in vivo, but their direct effects at a cellular level are not well characterized. Recently, CDs have garnered much interest because of their ability to clear stored cholesterol from Niemann Pick Type C (NPC) cells and markedly prolong the life of NPC1 disease mice. Here, we investigate the hypothesis that treatment with 2-hydroxypropyl- β-cyclodextrin (HPB-CD) stimulates lysosomal exocytosis in a calcium-enhanced manner. We propose that this exocytosis is the mechanism by which HPB-CD ameliorates the endolysosomal cholesterol storage phenotype in NPC cells. These findings have significant implications for the use of HPB-CD in biochemical assays and data interpretation as well as for their use for the treatment for NPC and other disorders

Data Management Applications for the Service Preparation Subsystem

These software applications provide intuitive User Interfaces (UIs) with a consistent look and feel for interaction with, and control of, the Service Preparation Subsystem (SPS). The elements of the UIs described here are the File Manager, Mission Manager, and Log Monitor applications. All UIs provide access to add/delete/update data entities in a complex database schema without requiring technical expertise on the part of the end users. These applications allow for safe, validated, catalogued input of data. Also, the software has been designed in multiple, coherent layers to promote ease of code maintenance and reuse in addition to reducing testing and accelerating maturity

MLN64 Transport to the Late Endosome Is Regulated by Binding to 14-3-3 via a Non-canonical Binding Site

MLN64 is an integral membrane protein localized to the late endosome and plasma membrane that is thought to function as a mediator of cholesterol transport from endosomal membranes to the plasma membrane and/or mitochondria. The protein consists of two distinct domains: an N-terminal membrane-spanning domain that shares homology with the MENTHO protein and a C-terminal steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain that binds cholesterol. To further characterize the MLN64 protein, full-length and truncated proteins were overexpressed in cells and the effects on MLN64 trafficking and endosomal morphology were observed. To gain insight into MLN64 function, affinity chromatography and mass spectrometric techniques were used to identify potential MLN64 interacting partners. Of the 15 candidate proteins identified, 14-3-3 was chosen for further characterization. We show that MLN64 interacts with 14-3-3 in vitro as well as in vivo and that the strength of the interaction is dependent on the 14-3-3 isoform. Furthermore, blocking the interaction through the use of a 14-3-3 antagonist or MLN64 mutagenesis delays the trafficking of MLN64 to the late endosome and also results in the dispersal of endocytic vesicles to the cell periphery. Taken together, these studies have determined that MLN64 is a novel 14-3-3 binding protein and indicate that 14-3-3 plays a role in the endosomal trafficking of MLN64. Furthermore, these studies suggest that 14-3-3 may be the link by which MLN64 exerts its effects on the actin-mediated endosome dynamics

Endosomal lipid accumulation in NPC1 leads to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment

Background information. Within the group of lysosomal storage diseases, NPC1 [NPC (Niemann-Pick type C) 1] disease is a lipidosis characterized by excessive accumulation of free cholesterol as well as gangliosides, glycosphingolipids and fatty acids in the late E/L (endosomal/lysosomal) system (Chen et al., 2005) due to defect in late endosome lipid egress. We have previously demonstrated that expression of the small GTPase Rab9 in NPC1 cells can rescues the lipid transport block phenotype (Walter et al., 2003), albeit by an undefined mechanism. Results. To investigate further the mechanism by which Rab9 facilitates lipid movement from late endosomes we sought to identify novel Rab9 binding/interacting proteins. In the present study, we report that Rab9 interacts with the intermediate filament phosphoprotein vimentin and this interaction is altered by lipid accumulation in late endosomes, which results in inhibition of PKC (protein kinase C) and hypophophoralation of vimentin, leading to late endosome dysfunction. Intermediate filament hypophosphorylation, aggregation and entrapment of Rab9 ultimately leads to transport defects and inhibition of lipid egress from late endosomes. Conclusions. These resutls reveal a previously unappreciated interaction between Rab proteins and intermediate filaments in regulating intracellular lipid transport. © The Authors Journal compilation

PKC activation in Niemann pick C1 cells restores subcellular cholesterol transport.

Activation of protein kinase C (PKC) has previously been shown to ameliorate the cholesterol transport defect in Niemann Pick Type C1 (NPC1) cells, presumably by increasing the soluble levels of one of its substrates, vimentin. This activity would then restore the vimentin cycle in these cells and allow vimentin-dependent retrograde transport to proceed. Here, we further investigate the effects of PKC activation in NPC1 cells by evaluating different isoforms for their ability to solubilize vimentin and correct the NPC1 cholesterol storage phenotype. We also examine the effects of PKC activators, including free fatty acids and the PKC-specific activator diazoxide, on the NPC1 disease phenotype. Our results indicate that PKC isoforms α, βII, and ε have the greatest effects on vimentin solubilization. Furthermore, expression or activation of PKCε in NPC1 cells dramatically reduces the amount of stored cholesterol and restores cholesterol transport out of endocytic vesicles. These results provide further support for the contribution of PKCs in NPC1 disease pathogenesis and suggest that PKCs may be targeted in future efforts to develop therapeutics for NPC1 disease

Filipin staining of free cholesterol in NPC1 cells treated with HPB-CD for 20 hours.

<p>Filipin intensity was quantitated in at least 150 cells for each sample. The bar graph represents average values from 3 independent experiments. *<i>P</i><0.0001.</p

HPB-CD toxicity in cell lines derived from BALB/c mice.

<p>Wt (squares) and NPC1 (circles) cells were treated with increasing concentrations of HPB-CD for 2 hours and their percent survival was determined using the MTT assay as described in “<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015054#s4" target="_blank">Materials and Methods</a>”. * and ** denote statistically significant differences between treated and untreated cells with <i>P</i><0.01 and <i>P</i><0.05, respectively.</p

Enlarged cholesterol-filled vesicles in NPC1 cells treated with HPB-CD.

<p>Cholesterol-filled vesicles fuse to form larger vesicles (arrows), the number of which increases with time. The bar graph represents the percentage of cells with at least one enlarged vesicle (with a minimum size of 10 microns) out of 150 cells and is representative of 2 independent experiments.</p